A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma
A Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of AK104 Plus Oxaliplatin and Capecitabine (XELOX) Versus Placebo Plus XELOX as First-line Treatment for Locally Advanced Unresectable or G/GEJ Adenocarcinoma
Sponsor: Akeso
A PHASE3 clinical study on Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, this trial is completed. The trial is conducted by Akeso and has accumulated 8 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Apr 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
Nov 2023 — May 2024 [monthly]
Recruiting PHASE3
-
Feb 2022 — Nov 2023 [monthly]
Recruiting PHASE3
-
Sep 2021 — Feb 2022 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Akeso
For direct contact, visit the study record on ClinicalTrials.gov .